Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Lirafugratinib is an oral, selective FGFR inhibitor that targets FGFR2 alterations driving tumour growth. It inhibits FGFR2 kinase signalling, reducing downstream pathway activation in FGFR2 fusion- or rearrangement-positive cholangiocarcinoma. The product label describes it as a kinase inhibitor.
Indications / reported uses
Treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harbouring an FGFR2 gene fusion or other rearrangement, under the US LYRFIGTU product label (approved September 23, 2026).
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Lirafugratinib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Lirafugratinib Permitted Daily Exposure (PDE) report (the Lirafugratinib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Lirafugratinib Occupational Exposure Limit (OEL) report (the Lirafugratinib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.